Last reviewed · How we verify
MMR vaccination
MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens.
MMR vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses through live attenuated viral antigens. Used for Prevention of measles, Prevention of mumps, Prevention of rubella.
At a glance
| Generic name | MMR vaccination |
|---|---|
| Sponsor | Klara M. Pósfay Barbe |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in vaccinated individuals but do not cause disease. This triggers both humoral (antibody) and cell-mediated immune responses, providing long-term protective immunity against these three viral infections. Upon exposure to wild-type virus, the primed immune system rapidly produces neutralizing antibodies and activates T cells to prevent infection or severe disease.
Approved indications
- Prevention of measles
- Prevention of mumps
- Prevention of rubella
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Rash
- Parotitis (mumps-like symptoms)
- Arthralgia or arthritis
Key clinical trials
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters (NA)
- Booster Dose of sIPV Co-administered With MMR and HepA-I. (PHASE4)
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer (PHASE1)
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMR vaccination CI brief — competitive landscape report
- MMR vaccination updates RSS · CI watch RSS
- Klara M. Pósfay Barbe portfolio CI